Holen Sie sich die Stockscreener-App
1.61
11.81%
0.17
Handel nachbörslich:
1.58
-0.03
-1.86%
Schlusskurs vom Vortag:
$1.44
Offen:
$1.44
24-Stunden-Volumen:
2.31M
Relative Volume:
1.13
Marktkapitalisierung:
$96.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.33M
KGV:
-0.8994
EPS:
-1.79
Netto-Cashflow:
$-39.53M
1W Leistung:
-0.62%
1M Leistung:
-53.74%
6M Leistung:
-47.21%
1J Leistung:
-59.85%
1-Tages-Spanne:
$1.385
$1.635
1-Wochen-Bereich:
$1.35
$1.71
52-Wochen-Spanne:
$1.35
$5.08
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Vergleichen Sie ELDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
1.61 | 108.05M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Guggenheim | Buy |
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Eledon Shares Fall Nearly 50% After Phase 2 Results - Orange County Business Journal
What drives Eledon Pharmaceuticals Inc stock priceSwing Trading Ideas & Small Entry Cost Trading - earlytimes.in
Midday Stock Roundup: RxSight up 14% - Orange County Business Journal
How analysts rate Eledon Pharmaceuticals Inc. stock todayWeekly Risk Summary & Growth Focused Stock Pick Reports - newser.com
Will Eledon Pharmaceuticals Inc. (2TK) stock test record highs in 20252025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock supported by strong fundamentalsJuly 2025 Closing Moves & High Return Stock Watch Alerts - newser.com
Eledon Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
How analysts revise price targets for Eledon Pharmaceuticals Inc. (2TK) stockWeekly Trade Report & AI Forecasted Entry and Exit Points - newser.com
What technical patterns form on Eledon Pharmaceuticals Inc. (2TK) stock chartsWeekly Gains Report & Accurate Entry/Exit Alerts - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock worth buying before Fed actionTrend Reversal & Free Safe Capital Growth Stock Tips - newser.com
Eledon Pharmaceuticals Inc. stock momentum explainedEarnings Beat & Free Community Consensus Stock Picks - newser.com
Why Eledon Pharmaceuticals Inc. (2TK) stock could be top winnerEarnings Trend Report & Long-Term Growth Portfolio Plans - newser.com
Can Eledon Pharmaceuticals Inc. (2TK) stock sustain margin levelsJuly 2025 EndofMonth & Capital Protection Trading Alerts - newser.com
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial - Clinical Trials Arena
Visual trend scoring systems applied to Eledon Pharmaceuticals Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
Market reaction to Eledon Pharmaceuticals Inc.’s recent newsTrade Signal Summary & Safe Capital Investment Plans - newser.com
Why Eledon Pharmaceuticals Inc. (2TK) stock stays on buy lists2025 Price Action Summary & Breakout Confirmation Alerts - newser.com
Eledon Pharmaceuticals stock rises after positive islet transplant data By Investing.com - Investing.com Australia
Eledon Pharmaceuticals stock rises after positive islet transplant data - Investing.com
Eledon’s anti-CD40L antibody shows promise in diabetes trial - Investing.com
Eledon reports preliminary data from first six patients with type 1 diabetes treated with tegoprubart as the core immunosuppressant - MarketScreener
Eledon Pharmaceuticals (ELDN) Reports Promising Trial Results fo - GuruFocus
Eledon Pharmaceuticals Reports Encouraging Preliminary Results for Tegoprubart in Islet Transplantation for Type 1 Diabetes - Quiver Quantitative
Eledon’s anti-CD40L antibody shows promise in diabetes trial By Investing.com - Investing.com Nigeria
Eledon (NASDAQ: ELDN) tegoprubart study: 6 T1D islet transplant patients insulin-free - Stock Titan
Guggenheim Lowers Price Target for ELDN While Maintaining Buy Ra - GuruFocus
Is Eledon Pharmaceuticals Inc. stock a buy in volatile marketsJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
Transcript : Eledon Pharmaceuticals, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-12-2025 10 - MarketScreener
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):